[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients

• Status: Recruiting
• Trial end date: 2023-12-12
• Target enrollment: 0
• Participant gender: Male

Summary

To investigate the radioactive uptake of [Al 18 F]PSMA137 in PCa patients, and evaluate the ability of [Al 18 F]PSMA137 to detect PSMA overexpression in PCa patients (especially those with recurrent or advanced PCa).To provide an approach for screening patients high expression of PSMA, efficacy monitoring, drug resistance and early warning of recurrence and metastasis to achieve the individualized antitumor treatment of targeted drugs.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Cancer Hospital
• Treatments: Choline

Criteria

Inclusion Criteria:

• Men over 18 years of age need to undergo [Al18F]PSMA137 PET/CT examination for suspected prostate cancer.

• The patients can fully understand and voluntarily participate in this experiment, and sign the informed consent.

Exclusion Criteria:

• Significant hepatic or renal dysfunction;

• Patients with malignant tumors other than prostate cancer within 2 years;

• Ready to pregnant;

• The patient can not tolerate all clinical tests.